Using empagliflozin to improve heart function in patients with pulmonary arterial hypertension
Official title: Master - 2/2 Empaglifozin To Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-10948583 · Data updated 2026-11-12
This study is looking at whether taking a daily medication called empagliflozin for 24 weeks can help improve heart function in people with pulmonary arterial hypertension (PAH), and it involves some tests to see how well your heart is working and how you feel overall.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2030 |
| Funding year | 2024 |
| Award (this year) | $371,492 |
| NIH project number | 1U24HL175028-01 |
| Project ID | NIH-10948583 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension who meet specific health criteria.
✕Less likely to help
Patients who do not have pulmonary arterial hypertension or those with contraindications to empagliflozin may not benefit from this research.
What this research studies
This research investigates the effects of empagliflozin, a medication taken daily for 24 weeks, on heart function in patients with pulmonary arterial hypertension (PAH). The study is a randomized, placebo-controlled trial conducted at three centers, where participants will undergo various assessments including cardiac imaging and quality of life evaluations. The primary goal is to determine if empagliflozin can enhance right ventricular function, measured through advanced imaging techniques. Patients will also be monitored for changes in exercise capacity and other health indicators throughout the trial.
Why it matters
Potential benefit: If successful, this research could lead to improved heart function and quality of life for patients suffering from pulmonary arterial hypertension.
How similar studies have gone: Previous research has shown promising results with similar medications in improving heart function, making this approach both relevant and potentially impactful.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Gassman, Jennifer J — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Gassman, Jennifer J
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.